Trial
NCT04160468
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
ContraFect
Collaborators
—
Condition
Staphylococcus Aureus Bacteremia
Intervention
Exebacase
Why stopped
The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-02